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Medication overuse headache (MOH) is a secondary
chronic headache with a prevalence of 1.7% in the general
population [1, 2]. The International Classiﬁcation of
Headache Disorders II (ICHD II) deﬁnes the overuse to be
C15 days/month for simple analgesic, or C10 days/month
for triptans, ergots, opioids, combination of analgesics or
acute medications for [3 months [3, 4]. The socio-eco-
nomic impact of MOH is enormous. Although direct data
are missing it is probably one of the most costly illnesses,
and the most costly headache. The current treatment
strategy for MOH is detoxiﬁcation. Detoxiﬁcation is usu-
ally a time consuming and complex course usually
requiring close interact between patient and physician, and
relapse is frequent [5].
The pilot study by the Comoestas Consortium explore
patients’ expectations and preferences for the treatment of
MOH [6]. They hypothesize that compliance and satis-
faction with treatment increase, if the patients have realistic
expectations. This is an important study, since it explores
the patients’ viewpoint rather than usual clinical trial pri-
mary and secondary end point such as reduction in head-
ache days or efﬁcacy of acute medication at 2 h.
The study included 65 consecutive patients with MOH
referred to either of three tertiary headache centers. The
participants ﬁlled in a questionnaire with three sections
exploring their needs for headache information, preference
for headache information and expectations of the headache
treatment.
Personal contact either by direct or by telephone was
both the preferred need and preference for headache
information prior to e-mail, website information, and
leaﬂets. This is in line with the fact that the patients did not
beneﬁt sufﬁciently from self-treatment. The internet pro-
vide enormous quantities of information of varied quality,
which is difﬁcult to analyze and use, while a leaﬂet might
not cover the speciﬁc disease in quest. The preference for
personal contact exist even thought the patients did not
beneﬁt sufﬁciently from the ﬁrst and second-line treatment.
Thus, the patients have more conﬁdence in advice from
health professionals than unsorted information from vari-
ous other sources. The preference for person contact direct
or by telephone prior to e-mail correspondance probably
reﬂect a combination of speed and possibility for direct
dialog.
The most common treatment expectations were reduc-
tion of the headache frequency and intensity. Fifteen and
eighteen percent of the patients did not had those expec-
tations, but since they showed up at the tertiary headache
clinic, they probably had some other expectations such as a
fast treatment or an effective previtive medication or it may
be educational information. Overall 59% had expectation
of a cure for their headache. This parameter showed the
largest variation between the three centres, as 80% of the
Italians, 45% of Germans and 50% Danes had this expec-
tation. The difference was not signiﬁcant probably to a type
2 error.
Finally this is an interesting and compelling pilot study
that focus on the patients’ perspective. Hopefully the
Comoestas Consortium will proceed on investigation the
patients need and expectations in a larger populations in the
future.
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